# EDGAR Filing Document

**Accession Number:** 0001750149
**File Stem:** 0001193125-25-146877
**Filing Date:** 2025-6
**Character Count:** 2512
**Document Hash:** 4a0161fef879555dff4e8365dc45749e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-146877.hdr.sgml**: 20250730

**ACCESSION NUMBER**: 0001193125-25-146877

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inhibikase Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001750149
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 263407249
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 N. WEST STREET, SUITE 1200
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** (302) 295-3800

**MAIL ADDRESS:**
- **STREET 1:** 1000 N. WEST STREET, SUITE 1200
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**<u>VIA EDGAR</u>**

June 25, 2025

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life

Sciences 100 F Street,

N.E. Washington,

D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **<u>Inhibikase Therapeutics, Inc.</u>**  |

---

**Acceleration Request for Registration Statement on Form S-3** 

**Filed June 20, 2025** 

**File No. 333-288213** 

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Inhibikase Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the above- referenced registration statement (the "**Registration Statement**") be accelerated to June 27, 2025, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our outside counsel, Goodwin Procter LLP, by calling Marishka DeToy at (617) 570-1926. If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926.

---

| |
|:---|
| Sincerely, |
| Inhibikase Therapeutics, Inc. |
| /s/ David McIntyre |
| David McIntyre |
| Chief Financial Officer |

---

cc: Mark Iwicki, *Inhibikase Therapeutics, Inc.* Danielle Lauzon, Esq., *Goodwin Procter LLP* <br> Marishka DeToy, Esq., *Goodwin Procter LLP*